Article Correctness Is Author's Responsibility: New advances in the treatment of advanced lung cancer

(University of Barcelona) The University of Barcelona (UB) and Hospital ClĂ­nic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer. This public-private collaboration enabled researchers identify molecular mechanisms underlying the lack of efficiency of this drug in squamous cell carcinoma, a sub-type of non-small cell lung cancer, and the important role of smoking in this lack of effectivity.